person · Reporting owner

Manning Paul B

Disclosed activity across 8 companies

Tapewire entity: 33957
SEC CIK: 0001494695

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Candel Therapeutics, Inc.CADL · Entity 4969	Director	September 30, 2026	October 02, 2026
Liquidia CorpLQDA · Entity 1860	Director	June 16, 2026	June 18, 2026
Pasithea Therapeutics Corp.KTTA · Entity 7685	10% owner	October 22, 2022	February 14, 2023
Verrica Pharmaceuticals Inc.VRCA · Entity 6823	Director · 10% owner	November 25, 2025	November 26, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Candel Therapeutics, Inc.

Report date September 30, 2026 · Filed October 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2036-09-30	Direct	2,189	Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 2,189 · Balance 2,189 F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.

Liquidia Corp

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	475,465	Reported balance After 2026-06-16 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 5,882 · Balance 475,465 F1: Represents restricted stock units ("RSUs"). The RSUs convert into common stock on a one-for-one basis and shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.
Common StockSEC Table I · non-derivative	Direct	3,131,794	Reported balance Holding disclosure · report date 2026-06-16 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,131,794 F2: The shares are held by Reporting Person jointly with his spouse.
Common StockSEC Table I · non-derivative	IndirectSee footnote	716,311	Reported balance Holding disclosure · report date 2026-06-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 716,311 F3: The securities are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectSee footnote	798,335	Reported balance Holding disclosure · report date 2026-06-16 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 798,335 F4: The shares are held directly by the Paul B. Manning Revocable Trust (the "PBM 2000 Trust"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	435,674	Reported balance Holding disclosure · report date 2026-06-16 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 435,674 F5: The securities are held by PBM Capital Finance, LLC ("PBM"). The Reporting Person is the manager and sole beneficial owner of PBM.
Common StockSEC Table I · non-derivative	IndirectSee footnote	198,413	Reported balance Holding disclosure · report date 2026-06-16 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 198,413 F6: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily, the manager of PD, and has shared voting and investment power with respect to the shares held by PD.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs"). The RSUs convert into common stock on a one-for-one basis and shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.

F2: The shares are held by Reporting Person jointly with his spouse.

F3: The securities are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

F4: The shares are held directly by the Paul B. Manning Revocable Trust (the "PBM 2000 Trust"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust.

F5: The securities are held by PBM Capital Finance, LLC ("PBM"). The Reporting Person is the manager and sole beneficial owner of PBM.

F6: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily, the manager of PD, and has shared voting and investment power with respect to the shares held by PD.

Pasithea Therapeutics Corp.

Report date October 22, 2022 · Filed February 14, 2023

Jointly reported with PD Joint Holdings, LLC Series 2016-A, Manning Bradford, Tiger Lily Capital, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,608,696	Reported balance Holding disclosure · report date 2022-10-22 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,608,696
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-06-21	Direct	Not disclosed	Reported balance Holding disclosure · report date 2022-10-22 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed

Verrica Pharmaceuticals Inc.

Report date November 25, 2025 · Filed November 26, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,958,189	Reported balance After 2025-11-25 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-11-25 · Purchase · Acquired 1,375,380 · Balance 3,958,189 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F2: The shares are held by Mr. Manning jointly with his spouse.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,348,372	Reported balance After 2025-11-25 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2025-11-25 · Purchase · Acquired 2,750,762 · Balance 3,348,372 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectSee footnote	25,663	Reported balance Holding disclosure · report date 2025-11-25 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 25,663 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F6: The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.
Series C Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.32 · Expires 2030-11-25	Direct	343,845	Reported balance After 2025-11-25 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-11-25 · Purchase · Acquired 343,845 · Balance 343,845 F8: The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F7: Immediately exercisable. F2: The shares are held by Mr. Manning jointly with his spouse.
Series C Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.32 · Expires 2030-11-25	IndirectSee footnote	687,690	Reported balance After 2025-11-25 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-11-25 · Purchase · Acquired 687,690 · Balance 687,690 F9: The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F7: Immediately exercisable. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectBy trust	89,187	Reported balance Holding disclosure · report date 2025-11-25 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 89,187 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy trust	89,187	Reported balance Holding disclosure · report date 2025-11-25 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 89,187 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy trust	89,187	Reported balance Holding disclosure · report date 2025-11-25 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 89,187 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy trust	332,433	Reported balance Holding disclosure · report date 2025-11-25 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 332,433 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F5: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.

F2: The shares are held by Mr. Manning jointly with his spouse.

F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.

F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F5: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.

F6: The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.

F7: Immediately exercisable.

F8: The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

F9: The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Acumen Pharmaceuticals, Inc.

Report date July 06, 2021 · Filed July 08, 2021

Section 16 reporting ended · disclosed 2021-07-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,040,193	Reported balance After 2021-07-06 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-07-06 · Conversion · Acquired 2,950,484 · Balance 3,040,193 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,352,693	Reported balance After 2021-07-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-07-06 · Purchase · Acquired 312,500 · Balance 3,352,693 F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	657,985	Reported balance After 2021-07-06 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-07-06 · Conversion · Acquired 657,985 · Balance 657,985 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-06 · Conversion · Disposed 1,634,515 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-06 · Conversion · Disposed 1,315,969 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-06 · Conversion · Disposed 657,985 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

Filing footnotes · ownership attribution and instrument terms

F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.

F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

AveXis, Inc.

Report date May 15, 2018 · Filed May 15, 2018

Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-05-15 transaction · row 1 1 source row Row 1 · 2018-05-15 · Disposition to issuer · Disposed 228,752 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Includes 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
Common StockSEC Table I · non-derivative	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-05-15 · Disposition to issuer · Disposed 1,201,160 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: These shares are held by PBM Capital Investments, LLC ("PBM"). The Reporting Person has the sole voting and investment power with respect to the shares held by the PBM. The Reporting Person disclaims beneficial ownership of the shares held by PBM except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2018-05-15 · Disposition to issuer · Disposed 25,293 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F4: These shares are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2026-02-10	Direct	Reported balance After 2018-05-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-05-15 · Disposition to issuer · Disposed 26,496 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.25 · Expires 2027-05-30	Direct	Reported balance After 2018-05-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-05-15 · Disposition to issuer · Disposed 2,454 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13	Direct	Reported balance After 2018-05-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-05-15 · Disposition to issuer · Disposed 2,905 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2025-05-04	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-05-15 · Disposition to issuer · Disposed 137,154 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F6: In connection with the transactions contemplated by the Merger Agreement, the Warrant was canceled in exchange for a lump sum cash payment equal to (i) the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by (ii) the number of shares of Common Stock underlying the Warrant. F7: The Warrant is held by PBM. Mr. Manning has the sole voting and investment power with respect to the shares issuable upon exercise of the Warrant held by PBM. Mr. Manning disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2024-03-07	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-05-15 · Disposition to issuer · Disposed 103,478 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F8: The amount reported reflects a pro rata distribution to members of PBM on August 15, 2016. In prior reports, the Reporting Person reported beneficial ownership of 130,623 shares of common stock underlying the Warrant. F9: Immediately exercisable. F7: The Warrant is held by PBM. Mr. Manning has the sole voting and investment power with respect to the shares issuable upon exercise of the Warrant held by PBM. Mr. Manning disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.

F2: Includes 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.

F3: These shares are held by PBM Capital Investments, LLC ("PBM"). The Reporting Person has the sole voting and investment power with respect to the shares held by the PBM. The Reporting Person disclaims beneficial ownership of the shares held by PBM except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F4: These shares are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.

F6: In connection with the transactions contemplated by the Merger Agreement, the Warrant was canceled in exchange for a lump sum cash payment equal to (i) the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by (ii) the number of shares of Common Stock underlying the Warrant.

F7: The Warrant is held by PBM. Mr. Manning has the sole voting and investment power with respect to the shares issuable upon exercise of the Warrant held by PBM. Mr. Manning disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F8: The amount reported reflects a pro rata distribution to members of PBM on August 15, 2016. In prior reports, the Reporting Person reported beneficial ownership of 130,623 shares of common stock underlying the Warrant.

F9: Immediately exercisable.

Dova Pharmaceuticals Inc.

Report date November 12, 2019 · Filed November 12, 2019

Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-11-12 transaction · row 1 1 source row Row 1 · 2019-11-12 · Other · Disposed 12,979,016 · Balance 0 F1: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 764,063 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship.
Common StockSEC Table I · non-derivative	IndirectBy LLC	0	Reported balance After 2019-11-12 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-11-12 · Other · Disposed 1,783,226 · Balance 0 F2: These shares are held by BKB Growth Investments, LLC ("BKB"). Manning is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. Manning disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 764,063 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship.

F2: These shares are held by BKB Growth Investments, LLC ("BKB"). Manning is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. Manning disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Taysha Gene Therapies, Inc.

Report date May 30, 2025 · Filed June 04, 2025

Section 16 reporting ended · disclosed 2025-06-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,841,704	Reported balance After 2025-05-30 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2025-05-30 · Purchase · Acquired 750,000 · Balance 2,841,704 F1: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectSee footnote	14,723,948.12	Reported balance Holding disclosure · report date 2025-05-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 14,723,948.12 F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16. F3: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Revocable Trust"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	22,000	Reported balance Holding disclosure · report date 2025-05-30 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 22,000 F4: The shares are held directly by BKB G2 Investments, LLC ("BKB G2"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB G2, and has shared voting and investment power with respect to the shares held by BKB G2.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,013,458.88	Reported balance Holding disclosure · report date 2025-05-30 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 4,013,458.88 F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16. F5: The shares are held directly by The PBM 2023 Grantor Retained Annuity Trust (the "2023 Annuity Trust"). The Reporting Person is the trustee of the 2023 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2023 Annuity Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,000,000	Reported balance Holding disclosure · report date 2025-05-30 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 4,000,000 F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16. F6: The shares are held directly by The PBM 2025 Grantor Retained Annuity Trust (the "2025 Annuity Trust"). The Reporting Person is the trustee of the 2025 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2025 Annuity Trust.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16.

F3: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Revocable Trust"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust.

F4: The shares are held directly by BKB G2 Investments, LLC ("BKB G2"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB G2, and has shared voting and investment power with respect to the shares held by BKB G2.

F5: The shares are held directly by The PBM 2023 Grantor Retained Annuity Trust (the "2023 Annuity Trust"). The Reporting Person is the trustee of the 2023 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2023 Annuity Trust.

F6: The shares are held directly by The PBM 2025 Grantor Retained Annuity Trust (the "2025 Annuity Trust"). The Reporting Person is the trustee of the 2025 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2025 Annuity Trust.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 05, 2022 Filed Jul 5, 2022 20:10 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	4,761,904	$2.10	$9,999,998.40	Disclosure SEC source: 0001209191-22-040581 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,651,128 F1 · ownership.direct: The shares are held by Mr. Manning jointly with his spouse. Read SEC document
June 17, 2022 Filed Jun 22, 2022 20:36 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	GrantStock Option (right to buy) · Derivative	15,500	$0.00 Strike: $2.81	$0.00	Disclosure SEC source: 0001209191-22-038685 · doc4.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2032-06-17 F1 · derivative.exercise_date: The shares vest on the earlier of June 17, 2023 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director though the applicable vesting date. Read SEC document
June 17, 2022 Filed Jun 22, 2022 20:31 UTC	Liquidia Corp LQDA · Entity 1860	GrantNon-Qualified Stock Option (right to buy) · Derivative	20,000	$0.00 Strike: $4.86	$0.00	Disclosure SEC source: 0001104659-22-073527 · tm2219055-3_4seq.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-17 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on June 17, 2025. Read SEC document
April 18, 2022 Filed Apr 19, 2022 20:30 UTC	Liquidia Corp LQDA · Entity 1860	PurchaseCommon Stock	392,156	$5.10	$1,999,995.60	Disclosure SEC source: 0001104659-22-047360 · tm2213052-1_4seq1.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,156 F1 · kind: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on April 18, 2022, and such shares of common stock are subject to a lock up agreement between the Reporting Person and BofA Securities, Inc.., pursuant to which the shares cannot be sold for 90 days following April 12, 2022. Read SEC document
March 31, 2022 Filed Apr 20, 2022 20:36 UTC	Liquidia Corp LQDA · Entity 1860	GrantCommon Stock	435,674	$0.00	$0.00	Disclosure SEC source: 0001104659-22-047871 · tm2213052-4_4seq1.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 435,674 F1 · kind: On March 31, 2022, 435,674 shares of the Issuer's common stock which were previously subject to a holdback pursuant to the terms of the merger agreement for Issuer's acquisition of RareGen, LLC ("RareGen") were released to the Reporting Person. The merger agreement provided that certain shares of the Issuer's common stock issuable to members of RareGen at the closing of the transaction would be held back as partial security for the benefit of the Issuer with respect to any indemnifiable damages pursuant to the indemnification obligations of the members of RareGen. The shares would subsequently be released for no additional consideration, subject to the cancellation of shares of the Issuer's common stock in connection with any such indemnifiable damages. F2 · ownership.nature: The securities are held by PBM Capital Finance, LLC ("PBM"). The Reporting Person is the manager and sole beneficial owner of PBM. Read SEC document
February 03, 2022 Filed Feb 4, 2022 13:28 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	26,602	$7.84	$208,559.68	Disclosure SEC source: 0001209191-22-007126 · doc4.xml · nonDerivative · entry 5 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,091,704 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.725 to $8.00 inclusive. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
February 03, 2022 Filed Feb 4, 2022 13:28 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	50,000	$7.84	$392,000.00	Disclosure SEC source: 0001209191-22-007126 · doc4.xml · nonDerivative · entry 4 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,202 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.725 to $8.00 inclusive. F2 · ownership.direct: Shares held by Mr. Manning jointly with his spouse. Read SEC document
February 02, 2022 Filed Feb 4, 2022 13:28 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	22,000	$7.77	$170,940.00	Disclosure SEC source: 0001209191-22-007126 · doc4.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.63 to $7.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (5). F4 · ownership.nature: The shares are held directly by BKB G2 Investments LLC ("BKB G2"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB G2, and has shared voting and investment power with respect to the shares held by BKB G2. Read SEC document
February 02, 2022 Filed Feb 4, 2022 13:28 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	45,000	$7.77	$349,650.00	Disclosure SEC source: 0001209191-22-007126 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,065,102 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.63 to $7.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (5). F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
February 02, 2022 Filed Feb 4, 2022 13:28 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	58,000	$7.77	$450,660.00	Disclosure SEC source: 0001209191-22-007126 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,202 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.63 to $7.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (5). F2 · ownership.direct: Shares held by Mr. Manning jointly with his spouse. Read SEC document
December 03, 2021 Filed Dec 6, 2021 13:20 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	19,977	$9.22	$184,187.94	Disclosure SEC source: 0001209191-21-068031 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,149,394 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.01 to $9.77 inclusive. F4 · balance_after: Consists of 7,754,783 shares of common stock held by Mr. Manning and 394,611 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
December 02, 2021 Filed Dec 6, 2021 13:20 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	30,023	$9.45	$283,717.35	Disclosure SEC source: 0001209191-21-068031 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,129,417 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.335 to $9.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3). F2 · balance_after: Consists of 7,754,783 shares of common stock held by Mr. Manning and 374,634 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
November 24, 2021 Filed Nov 29, 2021 22:01 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	2,202	$13.19	$29,044.38	Disclosure SEC source: 0001209191-21-067005 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,202 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.115 to $13.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: Shares held by Mr. Manning jointly with his spouse. Read SEC document
November 23, 2021 Filed Nov 24, 2021 12:58 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	20,000	$12.54	$250,800.00	Disclosure SEC source: 0001209191-21-066702 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.10 to $12.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: Shares held by Mr. Manning jointly with his spouse. Read SEC document
September 07, 2021 Filed Feb 15, 2022 02:16 UTC	Liquidia Corp LQDA · Entity 1860	GiftCommon Stock	4,460,308	$0.00	$0.00	Disclosure SEC source: 0001209191-22-009600 · doc5.xml · nonDerivative · entry 4 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,460,308 F3 · ownership.direct: The shares of are held by Reporting Person jointly with his spouse. Read SEC document
September 07, 2021 Filed Feb 15, 2022 02:16 UTC	Liquidia Corp LQDA · Entity 1860	GiftCommon Stock	4,460,308	$0.00	$0.00	Disclosure SEC source: 0001209191-22-009600 · doc5.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,413 F2 · ownership.nature: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of PD, and has shared voting and investment power with respect to the shares held by PD. Read SEC document
August 20, 2021 Filed Sep 1, 2021 21:24 UTC	Liquidia Corp LQDA · Entity 1860	GrantNon-Qualified Stock Option (right to buy) · Derivative	20,000	$0.00 Strike: $2.59	$0.00	Disclosure SEC source: 0001104659-21-112108 · tm2126786-6_4seq1.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-20 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024. Read SEC document
July 29, 2021 Filed Jul 30, 2021 01:02 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	PurchaseCommon Stock	20,000	$7.30	$145,944.00	Disclosure SEC source: 0000899243-21-030774 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 F3 · price: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.855 to $7.80. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F2 · ownership.direct: Shares held jointly with spouse. Read SEC document
July 29, 2021 Filed Aug 3, 2021 00:08 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	ConversionSeries B Preferred Stock · Derivative	1,361,069	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031096 · doc4.xml · derivative · entry 5 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By BKB Growth Investments, LLC Disclosed balance after: 0 Underlying: Common Stock · 553,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
July 29, 2021 Filed Aug 3, 2021 00:08 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	ConversionSeries B Preferred Stock · Derivative	1,669,303	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031096 · doc4.xml · derivative · entry 4 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Paul B. Manning Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 679,158 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
July 29, 2021 Filed Aug 3, 2021 00:08 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	ConversionCommon Stock	553,752	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-031096 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By BKB Growth Investments, LLC Disclosed balance after: 553,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
July 29, 2021 Filed Aug 3, 2021 00:08 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	ConversionCommon Stock	679,158	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-031096 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Paul B. Manning Revocable Trust Disclosed balance after: 679,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
July 29, 2021 Filed Aug 4, 2021 20:41 UTC Amendment	Candel Therapeutics, Inc. CADL · Entity 4969	ConversionSeries B Preferred Stock · Derivative	1,361,069	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031614 · doc4a.xml · derivative · entry 5 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By BKB Growth Investments, LLC Disclosed balance after: 0 Underlying: Common Stock · 553,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
July 29, 2021 Filed Aug 4, 2021 20:41 UTC Amendment	Candel Therapeutics, Inc. CADL · Entity 4969	ConversionSeries B Preferred Stock · Derivative	1,669,303	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031614 · doc4a.xml · derivative · entry 4 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Paul B. Manning Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 679,158 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
July 29, 2021 Filed Aug 4, 2021 20:41 UTC Amendment	Candel Therapeutics, Inc. CADL · Entity 4969	PurchaseCommon Stock	1,625,000	$8.00	$13,000,000.00	Disclosure SEC source: 0000899243-21-031614 · doc4a.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,681,000 F4 · ownership.direct: Includes shares held jointly with spouse. Read SEC document
July 29, 2021 Filed Aug 4, 2021 20:41 UTC Amendment	Candel Therapeutics, Inc. CADL · Entity 4969	ConversionCommon Stock	553,752	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-031614 · doc4a.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By BKB Growth Investments, LLC Disclosed balance after: 553,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
July 29, 2021 Filed Aug 4, 2021 20:41 UTC Amendment	Candel Therapeutics, Inc. CADL · Entity 4969	ConversionCommon Stock	679,158	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-031614 · doc4a.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Paul B. Manning Revocable Trust Disclosed balance after: 679,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
July 27, 2021 Filed Jul 30, 2021 01:02 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	PurchaseCommon Stock	36,000	$7.36	$264,834.00	Disclosure SEC source: 0000899243-21-030774 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 F1 · price: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.31 to $7.40. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F2 · ownership.direct: Shares held jointly with spouse. Read SEC document
July 14, 2021 Filed Feb 14, 2022 21:37 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GiftCommon Stock	36,752	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-006184 · doc5.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Paul B. Manning Revocable Trust Disclosed balance after: 642,406 F1 · kind: The shares reported herein reflect the final ownership of the Reporting Person as determined in accordance with the terms of the operating agreements of PBM ADV Holdings, LLC and PBM Capital Investments II, LLC. F1 · price: The shares reported herein reflect the final ownership of the Reporting Person as determined in accordance with the terms of the operating agreements of PBM ADV Holdings, LLC and PBM Capital Investments II, LLC. F1 · balance_after: The shares reported herein reflect the final ownership of the Reporting Person as determined in accordance with the terms of the operating agreements of PBM ADV Holdings, LLC and PBM Capital Investments II, LLC. F2 · ownership.nature: The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
July 06, 2021 Filed Jul 8, 2021 22:35 UTC	Acumen Pharmaceuticals, Inc. ABOS · Entity 6281	ConversionSeries B Preferred Stock · Derivative	657,985	$0.00	$0.00	Disclosure SEC source: 0001209191-21-046042 · doc4.xml · derivative · entry 6 Manning Paul B · CIK 0001494695 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 657,985 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
July 06, 2021 Filed Jul 8, 2021 22:35 UTC	Acumen Pharmaceuticals, Inc. ABOS · Entity 6281	ConversionSeries B Preferred Stock · Derivative	1,315,969	$0.00	$0.00	Disclosure SEC source: 0001209191-21-046042 · doc4.xml · derivative · entry 5 Manning Paul B · CIK 0001494695 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,315,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document
July 06, 2021 Filed Jul 8, 2021 22:35 UTC	Acumen Pharmaceuticals, Inc. ABOS · Entity 6281	ConversionSeries A-1 Preferred Stock · Derivative	1,634,515	$0.00	$0.00	Disclosure SEC source: 0001209191-21-046042 · doc4.xml · derivative · entry 4 Manning Paul B · CIK 0001494695 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,634,515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document
July 06, 2021 Filed Jul 8, 2021 22:35 UTC	Acumen Pharmaceuticals, Inc. ABOS · Entity 6281	ConversionCommon Stock	657,985	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-046042 · doc4.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 657,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
July 06, 2021 Filed Jul 8, 2021 22:35 UTC	Acumen Pharmaceuticals, Inc. ABOS · Entity 6281	PurchaseCommon Stock	312,500	$16.00	$5,000,000.00	Disclosure SEC source: 0001209191-21-046042 · doc4.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,352,693 F2 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document
July 06, 2021 Filed Jul 8, 2021 22:35 UTC	Acumen Pharmaceuticals, Inc. ABOS · Entity 6281	ConversionCommon Stock	2,950,484	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-046042 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,040,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document
July 06, 2021 Filed Feb 15, 2022 02:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	GiftCommon Stock	739,830	$0.00	$0.00	Disclosure SEC source: 0001209191-22-009596 · doc5.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,889,224 F2 · ownership.direct: Consists of 7,754,783 shares of common stock held by Mr. Manning and 1,134,441 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
July 06, 2021 Filed Feb 15, 2022 02:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	GiftCommon Stock	739,830	$0.00	$0.00	Disclosure SEC source: 0001209191-22-009596 · doc5.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document
July 06, 2021 Filed Feb 15, 2022 02:16 UTC	Liquidia Corp LQDA · Entity 1860	GiftCommon Stock	3,921,075	$0.00	$0.00	Disclosure SEC source: 0001209191-22-009600 · doc5.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,658,721 F2 · ownership.nature: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of PD, and has shared voting and investment power with respect to the shares held by PD. Read SEC document
July 06, 2021 Filed Feb 15, 2022 02:16 UTC	Liquidia Corp LQDA · Entity 1860	GiftCommon Stock	3,921,075	$0.00	$0.00	Disclosure SEC source: 0001209191-22-009600 · doc5.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · ownership.nature: The securities are held by PBM Capital Finance, LLC ("PBM"). The Reporting Person is the manager and sole beneficial owner of PBM. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:59 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	GrantStock Option (right to buy) · Derivative	15,500	$0.00 Strike: $25.04	$0.00	Disclosure SEC source: 0001209191-21-042087 · doc4.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2031-06-17 F1 · derivative.exercise_date: The shares vest on the earlier of June 17, 2022 or the next annual stockholders meeting, subject to continued service as a director though the applicable vesting date. Read SEC document
May 14, 2021 Filed May 17, 2021 11:48 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	12,000	$20.98	$251,760.00	Disclosure SEC source: 0001209191-21-033009 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.81 to $21.225 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: Shares held by Mr. Manning jointly with his spouse. Read SEC document
April 13, 2021 Filed Apr 15, 2021 13:24 UTC	Liquidia Corp LQDA · Entity 1860	PurchaseCommon Stock	198,413	$2.52	$500,000.76	Disclosure SEC source: 0001104659-21-050550 · tm2113044-2_4seq1.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 737,646 F1 · ownership.nature: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of PD, and has shared voting and investment power with respect to the shares held by PD. Read SEC document
March 25, 2021 Filed Mar 29, 2021 13:12 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	739,830	$14.75	$10,912,492.50	Disclosure SEC source: 0001209191-21-023388 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 739,830 F1 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document
March 24, 2021 Filed Mar 26, 2021 20:07 UTC	Liquidia Corp LQDA · Entity 1860	GrantNon-Qualified Stock Option (right to buy) · Derivative	21,385	$0.00 Strike: $2.51	$0.00	Disclosure SEC source: 0001104659-21-042434 · tm2111007-5_4seq1.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,385 Underlying: Common Stock · 21,385 shares Expires 2031-03-24 F1 · derivative.exercise_date: The option vests quarterly during 2021, with 25% of the option shares vesting on the date of grant, and 25% of the option shares vesting on each of June 30, 2021, September 30, 2021 and December 31, 2021, becoming fully vested on December 31, 2021. Read SEC document
December 31, 2020 Filed Feb 16, 2021 22:45 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	GiftCommon Stock	80,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-010878 · doc5.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,195,205 F1 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document
November 18, 2020 Filed Nov 19, 2020 21:10 UTC	Liquidia Corp LQDA · Entity 1860	GrantNon-Qualified Stock Option (right to buy) · Derivative	30,000	$0.00 Strike: $3.38	$0.00	Disclosure SEC source: 0001104659-20-127348 · a4.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-11-18 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments, becoming fully vested on November 18, 2023. Read SEC document
September 28, 2020 Filed Sep 30, 2020 20:37 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	ConversionSeries B Preferred Stock · Derivative	10,963	$0.00	$0.00	Disclosure SEC source: 0001209191-20-052459 · doc4.xml · derivative · entry 6 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 11,944 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
September 28, 2020 Filed Sep 30, 2020 20:37 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	ConversionSeries A Preferred Stock · Derivative	1,843,193	$0.00	$0.00	Disclosure SEC source: 0001209191-20-052459 · doc4.xml · derivative · entry 5 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,008,158 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
September 28, 2020 Filed Sep 30, 2020 20:37 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	ConversionSeries A Preferred Stock · Derivative	3,006,155	$0.00	$0.00	Disclosure SEC source: 0001209191-20-052459 · doc4.xml · derivative · entry 4 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 3,275,205 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F2 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document
September 28, 2020 Filed Sep 30, 2020 20:37 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	ConversionCommon Stock	11,944	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-052459 · doc4.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,020,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.